Trial Profile

An Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants With Angelman Syndrome

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 15 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rugonersen (Primary)
Indications Angelman syndrome
Focus Adverse reactions; First in man
Acronyms TANGELO
Sponsors Roche

Most Recent Events

15 Apr 2025 Results data from TANGELO study were presented at FAST's Annual Global Science Summit in November 2024.
15 Apr 2025 Results published in the Oak Hill Bio media release.
12 Sep 2024 Planned End Date changed from 3 Aug 2024 to 31 Jul 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com